Besides mutations in Notch1 and Notch2, approximately 50% of all human breast cancers show loss of Numb signaling, due to ubiquitination and degradation of Numb, which act as a tumor suppressor [44]. This evidence concerns the gene NOTCH2 and breast cancer.